Tocilizumab
Therapeutic Tocilizumab antibody from the original RoActemra® commercial drug.
Reference Standard as Aliquots
RoActemra®
Filters
Sort results
Reset
Apply
Product Batch | Therapeutic Expiry Date
| Brand & Origin
| Amount per Aliquot | Select Quantity | Discount | Price per Aliquot
| |
|---|---|---|---|---|---|---|---|
2021.10 |
RoActemra® DE |
2 mg |
Unit: aliquot(s) |
139,00 €
/aliquot
|
|||
2018.05 |
RoActemra® DE |
2 mg |
Unit: aliquot(s) |
139,00 €
/aliquot
|
|||
2019.03 |
RoActemra® DE |
2 mg |
Unit: aliquot(s) |
139,00 €
/aliquot
|
|||
2019.05 |
RoActemra® DE |
2 mg |
Unit: aliquot(s) |
139,00 €
/aliquot
|
|||
2020.03 |
RoActemra® DE |
2 mg |
Unit: aliquot(s) |
139,00 €
/aliquot
|
|||
2025.05 |
RoActemra® DE |
4 mg |
Unit: aliquot(s) |
245,00 €
/aliquot
|
Biosimilars as Aliquots
Access Batch Specific Analytical Information
Evidentic’s Analytical Data Service includes a comprehensive array of methods to support the drug development process, including structure, aggregation, degree of isomerization, and N-glycans identification of the active pharmaceutical ingredient (API).
Product Information
Here you will find the product information for the reference product.
RoActemra® / Tocilizumab Reference Product
| Drug name | RoActemra® |
| INN | Tocilizumab |
| API type | humanised IgG1 monoclonal antibody against the human interleukin-6 (IL-6) receptor produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology |
| Pharmacotherapeutic group | Immunosuppressants, Interleukin inhibitors |
| ATC code | L04AC07 |
| Target of antibody | IL-6 R; Synonyms: IL6R, il-6ra, CD126, IL-6R-1, IL-6RA, IL6Q, IL6RA, IL6RQ, gp80, IL6R1, Il6ra, IL-6Ralpha, IL6R, Il6r |
| General function | Tocilizumab is indicated for the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX and moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more diseasemodifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists. |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R). Tocilizumab has been shown to inhibit sIL-6R and mIL-6R-mediated signalling. IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, monocytes and fibroblasts. IL-6 is involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, induction of hepatic acute phase protein synthesis and stimulation of haemopoiesis. IL-6 has been implicated in the pathogenesis of diseases including inflammatory diseases, osteoporosis and neoplasia. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | In clinical studies with tocilizumab, rapid decreases in CRP, erythrocyte sedimentation rate (ESR) and serum amyloid A (SAA) were observed. Consistent with the effect on acute phase reactants, treatment with tocilizumab was associated with reduction in platelet count within the normal range. Increases in haemoglobin levels were observed, through tocilizumab decreasing the IL-6 driven effects on hepcidin production to increase iron availability. In tocilizumab-treated patients, decreases in the levels of CRP to within normal ranges were seen as early as week 2, with decreases maintained while on treatment. In healthy subjects administered tocilizumab in doses from 2 to 28 mg/kg, absolute neutrophil counts decreased to their lowest 3 to 5 days following administration. Thereafter, neutrophils recovered towards baseline in a dose dependent manner. Rheumatoid arthritis patients demonstrated a similar pattern of absolute neutrophil counts following tocilizumab administration (see section 4.8). |
| Original license holder | |
| Marketing authorisation numbers | EU/1/08/492/001 - 008 |
| Marketing authorisation holder | Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom |
| Name of the manufacturer of the biological active substance | Chugai Pharma Manufacturing Co., Ltd. 16-3 Kiyohara Kogyodanchi Utsunomiya City Tochigi, 321-3231 Japan Genentech Inc. One Antibody Way Oceanside CA 92056 USA |
| Name and address of the manufacturer(s) responsible for batch release | Roche Pharma AG Emil-Barell-Strasse 1 D-79639 Grenzach-Wyhlen Germany |
| Max shelf life | 30 months |
| Storage conditions | 2°C – 8°C |
| List of excipients | Sucrose Polysorbate 80 Disodium phosphate dodecahydrate Sodium dihydrogen phosphate dihydrate Water for injections |
Support
Do you have a question about the product? Reach out to our team using the form below – we’d be happy to help you!
Ready to simplify your sourcing?
Here’s how to get started:
Select Your Licensed Molecules
Browse our shop and choose the licensed molecule(s) you need. Don’t worry if you can’t find the molecule you’re looking for – we can source it for you!
Get a Quote
Receive a confidential, non-binding quote for the molecule(s) you choose.
Get Qualified & We Deliver
Complete our quick qualification process, place your order, and we’ll ship your molecule(s) within days.
Do you have a question you'd like to ask us?
Here’s how to get started:
